Eurofins Scientific SEERFSF -2.40%77 Cyclically Adjusted PB Ratio is 2.92 as of Jul. 06, 2026, which is 56% below its 10-year median of 6.69. GuruFocus rates ERFSF with a GF Scoreâ„¢ of 77/100 and a GF Valueâ„¢ of $74.92 (Fairly Valued). The stock has 7 warning signs investors should review. Among 136 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 69.12% on this metric.
The historical rank and industry rank for Eurofins Scientific SE's Cyclically Adjusted PB Ratio or its related term are showing as below:
ERFSF'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.33 Med: 6.69 Max: 16.91
Current: 3.07
During the past 13 years, Eurofins Scientific SE's highest Cyclically Adjusted PB Ratio was 16.91. The lowest was 2.33. And the median was 6.69.
ERFSF's Cyclically Adjusted PB Ratio is ranked worse than 69.12% of 136
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.835
vs ERFSF: 3.07
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Eurofins Scientific SE's adjusted book value per share data of for the fiscal year that ended in Dec25 was $30.108. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $26.53 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Eurofins Scientific SE (OTCPK:ERFSF) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Eurofins Scientific SE Cyclically Adjusted PB Ratio Related Terms
Eurofins Scientific SE Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Eurofins Scientific SE's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE Cyclically Adjusted PB Ratio Chart
ERFSF vs TMO, DHR, IDXX: Cyclically Adjusted PB Ratio Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Cyclically Adjusted PB Ratio falls into.
Eurofins Scientific SE Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 2.92 mean?
Eurofins Scientific SE (ERFSF) has a Cyclically Adjusted PB Ratio of 2.92 as of Jul. 06, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Eurofins Scientific SE and its competitors. This is 56% below median its historical median of 6.69. Over the past decade, Eurofins Scientific SE's Cyclically Adjusted PB Ratio has ranged from 2.33 to 16.91. According to the industry distribution chart, Eurofins Scientific SE ranks #94 out of 136 companies in the Medical Diagnostics & Research industry, placing it in the top 69.1%.
Is Eurofins Scientific SE's Cyclically Adjusted PB Ratio too high?
Eurofins Scientific SE's current Cyclically Adjusted PB Ratio of 2.92 is 56% below median its 10-year median of 6.69. Over the past 10 years, this metric has ranged from a low of 2.33 to a high of 16.91. The Medical Diagnostics & Research industry median Cyclically Adjusted PB Ratio is 1.84. Eurofins Scientific SE's value of 2.92 is 59.1% above this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #94 out of 136 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins Scientific SE has a GF Scoreâ„¢ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Cyclically Adjusted PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #94 out of 136 companies for Cyclically Adjusted PB Ratio. This places Eurofins Scientific SE in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.84. Eurofins Scientific SE's value of 2.92 is 59.1% above this benchmark. Historically, Eurofins Scientific SE's own Cyclically Adjusted PB Ratio has ranged from 2.33 to 16.91 over the past decade. While the company's 10-year median is 6.69 vs. the industry median of 1.84, Eurofins Scientific SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PB Ratio among Medical Diagnostics & Research companies is 1.84, based on 136 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current Cyclically Adjusted PB Ratio of 2.92 is 59.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PB Ratio is 1.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current Cyclically Adjusted PB Ratio is 2.92, which is 56% below median its own 10-year median of 6.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $74.92, compared to a current price of $77.54 — trading 3.5% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 2.92, which is 56% below median its 10-year median of 6.69 and 59.1% above the Medical Diagnostics & Research industry median of 1.84. Eurofins Scientific SE's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Cyclically Adjusted PB Ratio is 2.92 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $77.54 is trading 3.5% above its estimated GF Value™ of $74.92.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
Cyclically Adjusted PB Ratio: 2.92 (56% below median its 10-year median of 6.69)
GF Value™: $74.92 vs. price of $77.54 (3.5% above fair value)
Industry Position: 59.1% above the Medical Diagnostics & Research median (#94 of 136)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
77GF Score
Get the complete analysis for ERFSF
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
